SEARCH

SEARCH BY CITATION

References

  • Akhtar, S., El Weshi, A., Rahal, M., Abdelsalam, M., Al Husseini, H. & Magfoor, I. (2010) High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin’s lymphoma. Bone Marrow Transplantation, 45, 476482.
  • Aparicio, J., Segura, A., Garcera, S., Oltra, A., Santabella, A., Yuste, A. & Pastor, M. (1999) ESHAP is an effective regimen for relapsing Hodgkin’s disease. Annals of Oncology, 10, 593595.
  • Baker, K.S., Gordon, B.G., Gross, T.G., Abromowitch, M.A., Lyden, E.R., Lynch, J.C., Vose, J.M., Armitage, J.O., Coccia, P.F. & Bierman, P.J. (1999) Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin’s disease in children and adolescents. Journal of Clinical Oncology, 17, 825831.
  • Balwierz, W., Moryl-Bujakowska, A., Bogusławska-Jaworska, J., Pisarek, J., Raś, M., Sońta-Jakimczyk, D., Janik-Moszant, A., Rokicka-Milewska, R., Sopylo, B., Kolakowska-Mrozowska, B., Kołecki, P., Kaczmarek-Kanold, M., Kowalczyk, J., Odój, T., Matysiak, M. & Newecka-Samól, T. (2000) The incidence and treatment of the first relapse in children with Hodgkin’s disease. Medycyna Wieku Rozwojowego, 4, 7384.
  • Bath, L.E., Wallace, W.H. & Critchley, H.O. (2002) Late effects of the treatment of childhood cancer on the female reproductive system and the potential for fertility preservation. BJOG, 109, 107114.
  • Belgaumi, A., Al-Kofide, A.A., Jamil-Malik, R., Joseph, N., Khafaga, Y. & Sabbah, R. (2009) Outcome of second line therapy for pediatric patients with Hodgkin lymphoma who relapse following ABVD based therapy. Blood (ASH Annual Meeting Abstracts), 114: Abstract 2691.
  • Ben Arush, M.W., Solt, I., Lightman, A., Linn, S. & Kuten, A. (2000) Male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatric Hematology and Oncology, 17, 239245.
  • Bonfante, V., Santoro, A., Viviani, S., Devizzi, L., Balzarotti, M., Soncini, F., Zanini, M., Valagussa, P. & Bonadonna, G. (1997) Outcome of patients with Hodgkin’s disease failing after primary MOPP- ABVD. Journal of Clinical Oncology, 15, 528534.
  • Bonfante, V., Viviani, S., Devizzi, L., Di Russo, A., Di Nicola, M., Magni, M., Matteucci, P., Grisanti, S., Valagussa, P., Bonadonna, G. & Gianni, A.M. (2001) High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin’s disease. European Journal of Haematology, 64, 5155.
  • Bradley, M.B., Cooney, E., George, D., Garvin, J., Del Toro, G., Bhatia, M., Roman, E., Satwani, P., Militano, O., Cheung, Y.K., Kelly, K., van de Ven, C., Schwartz, J., Gewanter, R., Martin, P., Kutzberg, J. & Cairo, M.S. (2006). A pilot study of myeloablative (MA) autologous stem cell transplantation (AutoSCT) followed by reduced intensity (RI) allogeneic stem cell transplantation in children and adolescents with relapsed lymphoma. Biology of Blood and Marrow Transplantation, 12, 115. (abstract 330).
  • Brice, P. (2008) Managing relapsed and refractory Hodgkin lymphoma. British Journal of Haematology, 141, 313.
  • Brice, P., Bouabdallah, R., Moreau, P., Divine, M., Andre, A., Aoudjane, M., Fleury, J., Anglaret, B., Baruchel, A., Sensebe, L. & Colombat, P. (1997) Prognostic factors for survival after high-dose therapy and ASCT for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Bone Marrow Transplantation, 20, 2126.
  • Campbell, B., Wirth, A., Milner, A., Di Julio, J., MacManus, M. & Ryan, G. (2005) Long-term follow-up of salvage radiotherapy in Hodgkin’s lymphoma after chemotherapy failure. International Journal of Radiation Oncology Biology Physics, 63, 15381545.
  • Chen, A.R., Hutchison, R., Hess, A., Gardner, S., Trippett, T., de Alarcon, P., Hogan, S., Mitchell, J., Massey, V., Constine, L.S., Chen, L. & Schwartz, C.L. (2007) Clinical outcomes of patients with recurrent/refractory Hodgkin disease receiving cyclosporine, interferon-V and interleukin-2 immunotherapy to induce autoreactivity after autologous stem cell transplantation with BEAM: a COG study. Abstract #1896, Blood, 110 (11), A-1896, 2007.
  • Claviez, A., Kabisch, H., Suttorp, M., Peters, C., Hero, B., Schiller, I., Doerffel, W., Schmitz, N. & Zintl, F. (2004) The impact of disease status at transplant and time to first relapse on outcome in children and adolescents with Hodgkin’s lymphoma undergoing autologous stem cell transplantation. Blood (ASH Annual Meeting Abstracts), 104, 1878.
  • Claviez, A., Canals, C., Boogaerts, M., Stein, J., Mackinnon, S., Martino, R., Pession, A., Slavin, S., Craddock, C., Sakellari, I., Corradini, P., Rambaldi, A., Suttorp, M., Dini, G., Sureda, A. & Schmitz, N. (2007) The impact of allogeneic hematopoietic stem cell transplantation in children and adolescents with recurring Hodgkin’s lymphoma: an EBMT study on 151 patients. Blood (ASH Annual Meeting Abstracts), 110, 3061.
  • Claviez, A., Sureda, A. & Schmitz, N. (2008) Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin’s lymphoma. Bone Marrow Transplantation, 42, S16S24.
  • Claviez, A., Canals, C., Dierickz, D., Stein, J., Badell, I., Pession, A., Mackinnon, S., Slavin, S., Dalle, J.-H., Chacon, M., Wynn, R., Suttorp, M., Dini, G., Sureda, A. & Schmitz, N. (2009) Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood, 114, 20602067.
  • Cole, P.D., Schwartz, C.L., Drachtman, R.A., De Alarcon, P.A., Chen, L. & Trippett, T.M. (2009) Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin’s disease: a Children’s Oncology Group Report. Journal of Clinical Oncology, 27, 14561461.
  • Donaldson, S.S. & Link, M.P. (1997) Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin’s disease. Journal of Clinical Oncology, 5, 742749.
  • Donaldson, S.S., Link, M.P., Weienstein, H.J., Rai, S.N., Brain, S., Billett, A.L., Hurwitz, C.A., Krasin, M., Kun, L.E., Marcus, K.C., Tarbell, N.J., Young, J.A. & Hudson, M.M. (2007) Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin’s disease. Journal of Clinical Oncology, 25, 332337.
  • Dörffel, W., Luders, H., Ruhl, U., Albrecht, M., Marciniak, H., Parwaresch, R., Potter, R., Schellong, G., Schwarze, E.W. & Wickmann, L. (2003) Preliminary results of the multicenter trial GPOH-HD-95 for the treatment of Hodgkin’s disease in children and adolescents: analysis and outlook. Klinische Padiatrie, 215, 139145.
  • El- Badawy, S., Aboulnaga, S., Gabal, A.A., Mokhless, A., Zamzam, M., Sidhom, I., Ebeid, E. & Hussein, H. (2008) Risk adapted combined modality treatment in children with Hodgkin’s disease. Journal of the Egyptian National Cancer Institute, 20, 99110.
  • Fehniger, T.A., Larson, S. & Trinkaus, K. (2008) A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgkin lymphoma (cHL): preliminary results [abstract]. Blood, 112, 2595.
  • Frankovich, J., Donaldson, S.S., Lee, Y., Wong, R.M., Amylon, M. & Verneris, M.R. (2001) High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin’s disease: atopy predicts idiopathic diffuse lung injury syndromes. Biology of Blood and Marrow Transplantation, 7, 4957.
  • Harris, R.L., Termuelin, A., Cairo, M.S., Perkins, S.L., Gross, T.G. & Warkentin, P. (2006) Safety and efficacy of CBV followed by autologous PBSC transplant in children with lymphoma after failed induction or first relapse—a Children’s Oncology Group Study. Pediatric Blood and Cancer, 46, 843.
  • Hickish, T., Roldan, A., Cunningham, D., Mansi, J., Ashley, S., Nicolson, V., Gore, M.E., Catovsky, D. & Smith, I.E. (1993) EPIC: an effective low toxicity regimen for relapsing lymphoma. British Journal of Cancer, 68, 599604.
  • Hodgson, D.C., Hudson, M.M. & Constine, L.S. (2007) Pediatric Hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Seminars in Radiation Oncology, 17, 230242.
  • Hunger, S.P., Link, M.P. & Donaldson, S.S. (1994) ABVD/MOPP and low-dose involved field radiotherapy in Pediatric Hodgkin’s disease: the Stanford experience. Journal of Clinical Oncology, 12, 21602166.
  • Hutchinson, R.J., Fryer, C.J., Davis, P.C., Nachman, J., Krailo, M.D., O’Brien, R.T., Collins, R.D., Whalen, T., Reardon, D., Trigg, M.E. & Gilchrist, G.S. (1998) MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin’s disease in children: results of the children’s cancer group phase III trial. Journal of Clinical Oncology, 16, 897906.
  • James, N.D., Kingston, J.E., Plowman, P.N., Meller, S., Pinkerton, R., Barrett, A., Sandland, R., McElwain, T.J. & Malpas, J.S. (1992) Outcome of children with resistant and relapsed Hodgkin’s disease. British Journal of Cancer, 66, 11551158.
  • Johnston, P.B., Ansell, S.M. & Colgan, J.P. (2007) mTOR inhibition for relapsed or refractory Hodgkin lymphoma: promising single agent activity with everolimus (RAD001) [abstract]. Blood, 110, 2555.
  • Josting, A., Franklin, J., May, M., Koch, P., Beykirch, M.K., Heinz, J., Rudolph, C., Diehl, V. & Engert, A. (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. Journal of Clinical Oncology, 20, 221230.
  • Josting, A., Rudolph, C., Mapara, M., Glossman, J.P., Sienawski, S., Sieber, M., Kirchner, H.H., Dorken, B., Hossfeld, D.K., Kisro, J., Metzner, B., Berdel, W.E., Diehl, V. & Engert, A. (2005a) Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Annals of Oncology, 16, 116123.
  • Josting, A., Nogova, L., Franklin, J., Glossmann, J.P., Eich, H.T., Sieber, M., Scober, T., Boettcher, H.D., Schulz, U., Muller, R.P., Diehl, V. & Engert, A. (2005b) Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. Journal of Clinical Oncology, 23, 15221529.
  • Kuruvilla, J., Taylor, D., Wang, L., Blattler, C., Keating, A. & Crump, M. (2008) Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma [abstract]. Blood, 112, 3052.
  • van Leeuwen, F.E., Klokman, W.J., Stovall, M., Dahler, E.C., van’t Veer, M.B., Noordijk, E.M., Crommelin, M.A., Aleman, B.M., Broeks, A., Gospodarowicz, M., Travis, L.B. & Russell, N.S. (2003) Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. Journal National Cancer Institute, 95, 971980.
  • Leigh, B.R., Fox, K.A., Mack, C.F., Baier, M., Miller, T.P. & Cassady, J.R. (1993) Radiation therapy salvage of Hodgkin’s disease following chemotherapy failure. International Journal of Radiation Oncology Biology Physics, 27, 855862.
  • Leonard, J.P., Rosenblatt, J.D., Bartlett, N., Gopal, A., Younes, A., Fisher, D., Foss, F., Forero, A. & McDonald, M. (2004) Phase II study of SGN-30 (anti-CD30 monoclonal antibody in patients with refractory or recurrent Hodgkin’s disease. Blood (ASH Annual Meeting Abstracts), 104, 2635.
  • Lieskovsky, Y.E., Donaldson, S.S., Torres, M.A., Wong, R.M., Amylon, M.D., Link, M.P. & Agarwal, R. (2004) High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin’s disease: results and prognostic indices. Journal of Clinical Oncology, 22, 45324540.
  • Linch, D.C., Winfield, D., Goldstone, A.H., Moir, D., Hancock, B., McMillan, A., Chopra, R., Milligan, D. & Hudson, G.V. (1993) Dose intensification with ABMT in relapsed and resistant Hodgkin’s disease, results of a BNLI randomised trial. Lancet, 341, 10511054.
  • Longo, D.L., Duffey, P.L., Young, R.C., Hubbard, S.M., Ihde, D.C., Glatstein, E., Phares, J.C., Jaffe, E.S., Urba, W.J. & DeVita, Jr, V.T. (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. Journal of Clinical Oncology, 10, 210218.
  • Martin, A., Fernandez-Jimenez, M.C., Caballero, M.D., Canales, M.A., Perez-Simon, J.A., Garcia de Bustos, J., Vazquez, L., Hernandez-Navarro, F., San Miguel, J.F. (2001) Long term follow up in patients treated with Mini-Beam as salvage therapy for relapsed or refractory Hodgkin’s disease. British Journal of Haematology, 113 1, 161171.
  • Mertens, A.C., Yasui, Y., Neglia, J.P., Potter, J.D., Nesbit, M.E., Ruccione, K., Smithson, W.A. & Robison, L.L. (2001) Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. Journal of Clinical Oncology, 19, 31633172.
  • Metayer, C., Curtis, R.E., Vose, J., Sobocinski, K.A., Horowitz, M.M., Bhatia, S., Fay, J.W., Freytes, C.O., Goldstein, S.C., Herzig, R.H., Keating, K., Miller, C.B., Nevill, T.J., Pecora, A.L., Rizzo, J.D., Williams, S.F., Li, C.L., Travis, L.B. & Weisdorf, D.J. (2003) Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood, 101, 20152023.
  • Moller, T.R., Garwicz, S., Barlow, L., Winther, J.F., Glattre, E., Olafsdottir, G., Olsen, J.H., Perfekt, R., Ritvanen, A., Sankila, R. & Tulinius, H. (2001) Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. Journal of Clinical Oncology, 19, 31733181.
  • Moskowitz, C.H., Nimer, S.D., Zelenetz, A.D., Trippett, T., Hedrick, E.E., Filippa, D.A., Louie, D., Gonzales, M., Walitits, J., Coady-lyons, N., Qin, J., Franck, R., Bertino, J.R., Goy, A., Noy, A., O’Brien, J.P., Strauss, D., Portlock, C. & Yahalom, J. (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood, 97, 616623.
  • Moskowitz, C.H., Kewalramani, T., Nimer, S.D., Gonzales, M., Zelenetz, A.D. & Yahalom, J. (2004) Effectiveness of high-dose chemoradiotherapy and ASCT for patients with biopsy-proven primary refractory Hodgkin’s disease. British Journal Haematology, 124, 645652.
  • Moskowitz, C.H., Yahalom, J., Zelenetz, A.D., Zhang, Z., Filippa, D., Teruya-Feldstein, J., Kewalramani, T., Moskowitz, A.J., Rice, R.D., Maragulia, J., Vanak, J., Trippett, T., Hamlin, P., Horowitz, S., Noy, A., O’Connor, O.A., Portlock, C., Straus, D. & Nimer, S.D. (2010) High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. British Journal of Haematology, 148, 6.
  • Mundt, A.J., Sibley, G., Williams, S., Hallahan, D., Nautiyal, J. & Weichselbaum, R.R. (1995) Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin’s disease. International Journal of Radiation Oncology Biology Physics, 33, 261270.
  • Peggs, K.S., Hunter, A., Chopra, R., Parker, A., Mahendra, P., Milligan, D., Craddock, C., Pettengell, R., Dogan, A., Thomson, K.J., Morris, E., Hale, G., Waldmann, H., Goldstone, A.H., Linch, D.C. & Mackinnon, S. (2005) Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet, 365, 9475.
  • Peniket, A., Ruiz de Elvira, M., Taghipour, G., Cordonnier, C., Gluckman, E., de Witte, T., Santini, G., Blaise, D., Greinix, H., Ferrant, A., Cornelissen, J., Schmitz, N. & Goldstone, A. (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation s associated with a lower relapse rate but a higher procedure related mortality rate than autologous transplantation. Bone Marrow Transplantation, 31, 667678.
  • Poen, J.C., Hoppe, R.T. & Horning, S.J. (1996) High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: the impact of involved field radiotherapy on patterns of failure and survival. International Journal of Radiation Oncology Biology Physics, 36, 312.
  • Prete, A., Bonetti, F., Rondelli, R., Cesaro, S., Dallsorso, S., Favre, C., Fagioli, F., Messina, C., Burnelli, R., Locatelli, F. & Pession, A. (2005) High dose therapy (HDCT) and autologous haematopoietic stem cell transplantation (aSCT) in paediatric patients with recurrent or refractory Hodgkin’s disease (HD): results and outcome. Blood (ASH Annual meeting abstracts), 106, 2088.
  • Prince, H.M., George, D., Patnaik, A., Mita, M., Dugan, M., Butterfoss, D., Masson, E., Culver, K.W., Burris, H.A. & Beck, J. (2007) Phase I study oral LBH589, a novel deacetylase (DAC) inhibitor advanced solid tumors and non-Hodgkin’s lymphoma abstract]. Journal of Clinical Oncology, 25, 3500.
  • Proctor, S.J., Jackson, G.H., Lennard, A., Angus, B., Wood, K., Lucraft, H.L., White, J., Windebank, K. & Taylor, P.R.A. (2003) Strategic approach to the management of Hodgkin’s disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). Annals of Oncology, 14, i47i50.
  • Robinson, S., Sureda, A., Canals, C., Russell, N., Caballero, D., Bacigalupo, A., Iriondo, A., Cook, G., Pettitt, A., Socie, G., Bonifazi, F., Bosi, A., Michallet, M., Liakopolou, E., Maertens, J., Passweg, J., Clarke, F., Martino, R. & Schmitz, R.N. (2008) Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s Lymphoma: identification of prognostic factors predicting outcome. Hematologica, 94, 230238.
  • Ruffer, J.U., Ballova, V., Glossman, J., Sieber, M., Franklin, J., Nogova, L., Diehl, V. & Josting, A. (2005) BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease – results of the German Hodgkin Study Group. Leukemia and Lymphoma, 46, 15611567.
  • Santoro, A., Magagnoli, M., Spina, M., Pinotti, G., Siracusano, L., Michieli, M., Nozza, A., Morenghi, E., Castagna, L., Tirelli, U. & Balzarotti, M. (2007) Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica, 92, 3541.
  • Schellong, G. (1996) Treatment of children and adolescents with Hodgkin’s disease: the experience of the German-Austrian Paediatric Study Group. Baillieres Clinical Haematology, 9, 619634.
  • Schellong, G., Brämswig, J., Ludwig, R., Gerein, V., Jobke, A., Jürgens, H., Kabisch, H., Stollmann, B., Weinel, P. & Gadner, Hl. (1986) Combined treatment strategy in over 200 children with Hodgkin’s disease: graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy. A report of the cooperative therapy study DAL-HD-82. Klinische Pädiatrie, 198, 137146.
  • Schellong, G., Potter, R., Bramswig, J., Wagner, J., Prott, F.J., Dorffel, W., Korholz, D., Mann, G., Rath, B., Reiter, A., Weissbach, G., Roepenhausen, M., Thiemann, M. & Schwarze, E.W. (1999) High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: the German-Austrian multicenter trial DAL-HD-90: the German-Austrian Pediatric Hodgkin’s Disease Study Group. Journal of Clinical Oncology, 17, 37363744.
  • Schellong, G., Dorffel, W., Claviez, A., Korholz, D., Mann, G. & Scheel-Walter, H.G. (2005) Salvage therapy of progressive and recurrent Hodgkin’s disease: results from a multicenter study of the Pediatric DAL/GPOH-HD Study Group. Journal of Clinical Oncology, 23, 61816189.
  • Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A.M., Haenel, M., Boissevain, F., Zschaber, R., Muller, P., Kirchner, H., Lohri, A., Decker, S., Koch, B., Hasenclever, D., Goldstone, A.H. & Diehl, V. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with ASCT for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet, 325, 20652071.
  • Schnell, R., Dietlein, M., Staak, J.O., Borchman, P., Schomaeker, K., Fisher, T., Eschner, W., Hansen, H., Morschhauser, F., Schicha, H., Diehl, V., Raubitschek, A. & Engert, A. (2005) Treatment of refractory Hodgkin lymphoma patients with an Iodine-131 labeled murine anti-CD30 monoclonal antibody. Journal of Clinical Oncology, 23, 46694678.
  • Schwartz, C.L., Constine, L.S., Villaluna, D., London, W.B., Hutchison, R.E., Sposto, R., Lipshultz, S.E., Turner, C.S., deAlarcon, P.A. & Chauvenet, A. (2009) A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate and high-risk Hodgkin lymphoma: the results of P9425. Blood, 114, 20512059.
  • Scottish Intercollegiate Guidelines Network (SIGN) (2004) Long term follow up of survivors of childhood cancer. A national clinical guideline. Guideline 76. http://www.sign.ac.uk/pdf/sign76.pdf .
  • Shafer, J.A., Heslop, H.E., Brenner, M.K., Carrum, G., Wu, M.F., Liu, H., Ahmed, N., Gottschalk, S., Kamble, R., Leung, K.S., Myers, G.D., Bollard, C.M. & Krance, R.A. (2010) Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin’s lymphoma in adolescents and young adults at a single institution. Leukaemia and Lymphoma, 4, 664670.
  • Shankar, A.G., Ashley, S., Radford, M., Barrett, A., Wright, D. & Pinkerton, C.R. (1997) Does histology influence outcome in childhood hodgkin’s disease? Results From the United Kingdom Children’s Cancer Study Group. Journal of Clinical Oncology, 15, 26222630.
  • Skinner, R., Wallace, W.H. & Levitt, G.A. (2006) Long-term follow-up of people who have survived cancer during childhood. Lancet Oncology, 7, 489498.
  • Smith, R.S., Chen, Q., Hudson, M.M., Link, M.P., Kun, L., Weinstein, H., Billett, A., Marcus, K.J., Tarbell, N.J. & Donaldson, S.S. (2003) Prognostic factors for children with Hodgkin’s disease treated with combined-modality therapy. Journal of Clinical Oncology, 21, 20262033.
  • Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Maertens, J., Bormans, G., Thomas, J., Balzarini, J., De Wolf-Peters, C., Mortelmans, L. & Verhoef, G. (2003) Prognostic value of pretransplantation positron emission tomography using fluorine18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood, 102, 5359.
  • Stoneham, S., Ashley, S., Pinkerton, R., Wallace, W.H. & Shankar, A.G. (2004) Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. Journal of Pediatric Hematology and Oncology, 26, 740745.
  • Sureda, A., Robinson, S., Canals, C., Carella, A., Boogaerts, M., Caballero, D., Hunter, A., Kanz, L., Slavin, S., Cornelissen, J., Gramatzki, M., Niederwierser, D., Russell, N. & Schmitz, N. (2008) Reduced intensity conditioning compared with conventional allogeneic stem cell transplantation in relapsed or refractory Hodgkins lymphoma: an analysis from the Lymphoma Working Party of the European Group for blood and marrow transplantation. Journal of Clinical Oncology, 26, 455462.
  • Travis, L.B., Hill, D.A., Dores, G.M., Gospodarowicz, M., van Leeuwen, F.E., Holowaty, E., Glimelius, B., Andersson, M., Wiklund, T., Lynch, C.F., Van’t Veer, M.B., Glimelius, I., Storm, H., Pukkala, E., Stovall, M., Curtis, R., Boice, J.D. & Gilbert, E. (2003) Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. Journal of the American Medical Association, 23, 290.
  • Travis, L.B., Hill, D., Dores, G.M., Gospodarowicz, M., van Leeuwen, F.E., Holowaty, E., Glimelius, B., Andersson, M., Pukkala, E., Lynch, C.F., Pee, D., Smith, S.A., Van’t Veer, M.B., Joensuu, T., Storm, H., Stovall, M., Boice, J.D., Gilbert, E. & Gail, M.H. (2005) Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. Journal of the National Cancer Institute, 5, 97.
  • Vassilakopoulos, T.P., Angelopoulou, M.K., Siakantaris, M.P., Kontopidou, F.N., Dimopoulou, M.N., Boutsis, D.E., Anargyrou, K., Kokoris, S.I., Giannakakis, A., Karkantaris, C., Kyrtsonis, M.C., Tsaftaridis, P., Rombos, J., Variamis, E., Korkolopoulou, P., Kittas, C. & Pangalis, G.A. (2002) Prognostic factors in advanced stage Hodgkin’s lymphoma: the significance of the number of involved anatomic sites. European Journal of Haematology, 67, 279288.
  • Vecchi, V., Pileri, S., Burnelli, R., Bontempi, N., Comelli, A., Testi, A.M., Carli, M., Sotti, G., Rosati, D., Di Tullio, M.T., Grazia, G., Massolo, F., Arid, M., Colella, R., Pession, S.A., Rondelli, R. & Paolucci, G. (1993) Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer, 72, 20492057.
  • Vecchi, V., Burnelli, R., Di Fabio, F. & Frezza, G. (1997) Childhood Hodgkin’s disease: results of the Italian multicentric study AIEOP-MH’89-CNR. Medical Paediatric Oncology, 29, 5,434.
  • Verdeguer, A., Pardo, N., Madero, L., Martinez, A., Bureo, E., Fernandez, J.M., Munoz, A., Olive, T., Fernandez-Delgado, R., Diaz, M.A. & Sastre, A. (2000) Autologous stem cell transplantation for advanced Hodgkin’s disease in children. Bone Marrow Transplantation, 25, 3134.
  • Wallace, W.H. & Barr, R.D. (2010) Fertility preservation for girls and young women with cancer: what are the remaining challenges? Human Reproduction Update, 16 (6), 614616.
  • Wallace, W.H., Anderson, R.A. & Irvine, D.I. (2005) Fertility preservation for young people with cancer: who is at risk and what can be offered? Lancet Oncology, 6, 209218.
  • Wedgwood, A.R., Fanale, M.A., Fayad, L.E., McLaughlin, P., Hagemeister, F.B., Pro, B., Romaguera, J., Rodriguez, M.A., Samaniego, F. & Younes, A. (2007) Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) groups and in patients who have PET positive disease after 2–3 cycles of therapy [abstract]. Blood, 110, 215.
  • Williams, C.D., Goldstone, A.H., Pearce, R., Green, S., Armitage, J.O., Carella, A. & Meloni, G. (1993) Autologous bone marrow transplantation for pediatric Hodgkin’s disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. Journal of Clinical Oncology, 11, 22432249.
  • Wimmer, R.S., Chauvenet, A.R., London, W.B., Villaluna, D., de Alarcon, P.A. & Schwartz, C.L. (2006) APE chemotherapy for children with relapsed Hodgkin’s disease: a Paediatric Oncology Group Trial. Paediatric Blood and Cancer, 46, 320324.
  • Younes, A., Romaguera, J., Hagemeister, F., McLaughlin, P., Rodriguez, M.A., Fiumara, P., Goy, A., Jeha, S., Manning, J.T., Jones, D., Abruzzo, L.V. & Medeiros, L.D. (2003) A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer, 98, 310314.
  • Younes, A., Pro, B. & Fayad, L. (2006) Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood, 107, 17311732.
  • Younes, A., Forero-Torres, A., Bartlett, N.L., Leonard, J.P., Lynch, C., Kennedy, D.A. & Sievers, E. (2008) Multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas [abstract]. Blood, 112, 1006.
  • Younes, A., Sureda, A., Ben-Yehuda, D., Ong, T.C., Tan, D., Engert, A., Le Corre, C., Gallagher, J., Hirawat, S. & Prince, M. (2009) Phase II study of oral panobinostat in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant (ASCT) [abstract]. Haematologica, 94, 34.